Profile data is unavailable for this security.
About the company
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
- Revenue in USD (TTM)1.22bn
- Net income in USD79.96m
- Incorporated1981
- Employees3.10k
- LocationBio-Techne Corp614 Mckinley Pl N E, Suite 1500MINNEAPOLIS 55413United StatesUSA
- Phone+1 (612) 379-8854
- Fax+1 (612) 656-4400
- Websitehttps://www.bio-techne.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Immunitybio Inc | 82.56m | -348.62m | 6.83bn | 673.00 | -- | -- | -- | 82.68 | -0.4079 | -0.4079 | 0.0965 | -0.5323 | 0.1869 | 0.0857 | 4.56 | 121,404.40 | -78.93 | -109.27 | -91.33 | -251.12 | 90.40 | -- | -422.38 | -11,599.51 | 5.65 | -2.20 | 2.77 | -- | 2,270.58 | 46.27 | 29.09 | -- | 9.95 | -- |
| Belite Bio Inc (ADR) | 0.00 | -49.38m | 6.87bn | 25.00 | -- | 39.94 | -- | -- | -1.55 | -1.55 | 0.00 | 4.58 | 0.00 | -- | -- | 0.00 | -36.85 | -- | -36.85 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -14.26 | -- | -- | -- |
| Cytokinetics, Inc. | 87.21m | -751.94m | 7.75bn | 498.00 | -- | -- | -- | 88.83 | -6.31 | -6.31 | 0.7328 | -4.27 | 0.0607 | -- | 85.00 | 175,122.50 | -52.35 | -45.50 | -57.39 | -50.38 | -- | -- | -862.21 | -748.37 | -- | -14.45 | 1.96 | -- | 145.34 | -7.22 | -12.03 | -- | 8.32 | -- |
| Vaxcyte Inc | 0.00 | -657.20m | 7.84bn | 414.00 | -- | 2.50 | -- | -- | -4.84 | -4.84 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -19.53 | -26.00 | -20.51 | -27.91 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -15.33 | -- | 151.05 | -- |
| Nuvalent Inc | 0.00 | -381.44m | 7.95bn | 218.00 | -- | 8.80 | -- | -- | -5.32 | -5.32 | 0.00 | 11.70 | 0.00 | -- | -- | 0.00 | -35.18 | -25.32 | -37.61 | -26.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -106.59 | -- | -- | -- |
| Praxis Precision Medicines Inc | 7.46m | -273.04m | 8.76bn | 116.00 | -- | 19.69 | -- | 1,173.48 | -12.90 | -12.90 | 0.3533 | 16.23 | 0.0184 | -- | -- | 64,336.21 | -67.20 | -70.37 | -75.12 | -79.85 | -- | -- | -3,658.53 | -6,809.15 | -- | -- | 0.00 | -- | 249.53 | -- | -48.30 | -- | -- | -- |
| Arrowhead Pharmaceuticals Inc | 1.09bn | 202.27m | 8.77bn | 711.00 | 40.65 | 15.14 | 33.91 | 8.04 | 1.54 | 1.54 | 7.90 | 4.14 | 0.8335 | -- | 9.86 | 1,534,432.00 | 17.84 | -25.96 | 21.44 | -30.82 | -- | -- | 21.41 | -76.01 | -- | 5.91 | 0.5068 | -- | 23,258.15 | 56.63 | 99.73 | -- | 13.66 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.02bn | -83.48m | 9.14bn | 18.60k | -- | 2.68 | 26.30 | 2.27 | -1.56 | -1.56 | 80.18 | 69.20 | 0.5186 | 8.23 | 5.41 | 216,328.20 | -1.03 | 5.12 | -1.20 | 6.01 | 34.68 | 36.56 | -1.98 | 9.47 | 1.10 | 3.18 | 0.388 | 0.00 | -1.92 | 9.09 | -97.83 | -47.25 | 10.64 | -- |
| Tempus AI Inc | 1.11bn | -203.88m | 10.16bn | 2.40k | -- | 20.00 | -- | 9.19 | -1.18 | -1.18 | 6.45 | 2.86 | 0.6795 | 9.29 | 5.15 | 460,524.20 | -12.53 | -53.69 | -15.38 | -72.10 | 61.73 | 45.68 | -18.45 | -84.29 | 3.12 | -3.83 | 0.7104 | -- | 30.38 | 62.05 | -180.61 | -- | 5.36 | -- |
| BIO-TECHNE Corp | 1.22bn | 79.96m | 10.24bn | 3.10k | 129.01 | 5.08 | 55.76 | 8.43 | 0.5076 | 0.5076 | 7.74 | 12.90 | 0.4682 | 2.06 | 6.04 | 392,121.60 | 3.08 | 7.62 | 3.27 | 8.13 | 66.60 | 67.49 | 6.58 | 16.74 | 3.08 | 56.92 | 0.1145 | 26.72 | 5.23 | 10.55 | -56.35 | -20.37 | -9.74 | -4.36 |
| Madrigal Pharmaceuticals Inc | 740.64m | -289.13m | 11.09bn | 528.00 | -- | 17.72 | -- | 14.97 | -13.01 | -13.01 | 33.39 | 27.56 | 0.6082 | 0.9008 | 10.30 | 1,402,727.00 | -23.74 | -68.48 | -30.98 | -85.32 | 95.25 | -- | -39.04 | -876.55 | 3.26 | -- | 0.3519 | -- | -- | -- | -24.69 | -- | 106.52 | -- |
| Summit Therapeutics Inc | 0.00 | -921.62m | 11.14bn | 159.00 | -- | 57.96 | -- | -- | -1.24 | -1.24 | 0.00 | 0.2583 | 0.00 | -- | -- | 0.00 | -241.08 | -78.31 | -287.72 | -86.84 | -- | -- | -- | -31,307.77 | -- | -- | 0.00 | -- | -- | -- | 64.01 | -- | -16.43 | -- |
| Exelixis Inc | 2.29bn | 677.90m | 11.78bn | 1.15k | 18.50 | 5.45 | 16.65 | 5.15 | 2.38 | 2.38 | 8.00 | 8.06 | 0.7913 | 3.19 | 7.90 | 1,994,959.00 | 23.44 | 9.51 | 27.03 | 10.77 | 96.63 | 96.32 | 29.63 | 15.61 | 3.68 | -- | 0.00 | 0.00 | 18.49 | 17.51 | 150.89 | 10.18 | 17.25 | -- |
| ICON PLC | 8.10bn | 599.48m | 11.80bn | 39.80k | 20.89 | 1.26 | 11.94 | 1.46 | 7.40 | 7.40 | 101.04 | 122.25 | 0.4806 | -- | 3.00 | 193,379.50 | 3.56 | 3.70 | 4.33 | 4.46 | 28.15 | 29.00 | 7.40 | 7.41 | -- | 5.94 | 0.2675 | -- | 1.99 | 24.17 | 29.26 | 16.18 | 27.11 | -- |
| Regencell Bioscience Holdings Ltd | 0.00 | -3.58m | 13.70bn | 12.00 | -- | 2,819.75 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.0098 | 0.00 | -- | -- | 0.00 | -50.50 | -53.93 | -53.75 | -65.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 16.68 | -- | 5.32 | -- |
Data as of Feb 10 2026. Currency figures normalised to Bio-Techne Corp's reporting currency: US Dollar USD
38.33%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 16.43m | 10.55% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 8.79m | 5.64% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 5.75m | 3.69% |
| Atlanta Capital Management Co. LLCas of 30 Sep 2025 | 4.94m | 3.17% |
| Geode Capital Management LLCas of 30 Sep 2025 | 4.93m | 3.16% |
| Wellington Management Co. LLPas of 30 Sep 2025 | 4.88m | 3.13% |
| Invesco Capital Management LLCas of 30 Sep 2025 | 3.92m | 2.52% |
| Massachusetts Financial Services Co.as of 31 Dec 2025 | 3.66m | 2.35% |
| Neuberger Berman Investment Advisers LLCas of 30 Sep 2025 | 3.31m | 2.12% |
| T. Rowe Price Associates, Inc. (IM)as of 30 Sep 2025 | 3.12m | 2.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
